TargetMol

Eptifibatide

Product Code:
 
TAR-T5020
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T5020-5mg5mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5020-10mg10mg£116.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5020-25mg25mg£144.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5020-50mg50mg£188.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5020-100mg100mg£257.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Eptifibatide, an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class, is a cyclic heptapeptide constructed from 6 amino acids and a mercaptopropionyl residue.
CAS:
148031-34-9
Formula:
C35H49N11O9S2
Molecular Weight:
831.96
Purity:
0.98
SMILES:
NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O

References

van Rensburg, W.J.J., Roodt, J.P., Lamprecht, S. et al. Clin Exp Med (2012) 12: 257. https://doi.org/10.1007/s10238-011-0171-4 Mosawy, S., Jackson, D., Woodman, O., & Linden, M. (2012). Inhibition of platelet-mediated arterial thrombosis and platelet granule exocytosis by 3?,4?-dihydroxyflavonol and quercetin.?Platelets,?24(8), 594-604. doi: 10.3109/09537104.2012.749396